Goldman Sachs Group Inc. Has $91.57 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Goldman Sachs Group Inc. grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 24.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,018,387 shares of the medical equipment provider’s stock after acquiring an additional 199,446 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Zimmer Biomet were worth $91,573,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Zimmer Biomet by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after buying an additional 192,517 shares during the last quarter. Dodge & Cox increased its holdings in Zimmer Biomet by 5.1% during the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after buying an additional 1,118,710 shares during the last quarter. Capital International Investors increased its holdings in Zimmer Biomet by 11.5% during the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after buying an additional 778,467 shares during the last quarter. Geode Capital Management LLC increased its holdings in Zimmer Biomet by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider’s stock worth $468,821,000 after buying an additional 36,611 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Zimmer Biomet by 1.6% during the third quarter. Ameriprise Financial Inc. now owns 3,789,200 shares of the medical equipment provider’s stock worth $373,239,000 after buying an additional 58,335 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Trading Up 2.8%

Shares of Zimmer Biomet stock opened at $89.72 on Wednesday. The firm has a 50-day moving average of $87.68 and a 200-day moving average of $90.48. The stock has a market cap of $17.36 billion, a PE ratio of 23.30, a PEG ratio of 2.02 and a beta of 0.47. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s payout ratio is presently 24.94%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Truist Financial restated a “hold” rating and set a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a report on Wednesday, April 29th. JPMorgan Chase & Co. lowered their target price on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a report on Wednesday, April 29th. Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, April 7th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $102.70.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.